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Definition: Diabetic foot as defined by the World Health 
Organization (WHO) as, ‘The foot of a diabetic patient that has the 
potential risk of pathologic consequences, including infection, 
ulceration, and/or destruction of deep tissues associated with 
neurologic abnormalities, various degrees of peripheral vascular 
disease, and/or metabolic complications of diabetes in the lower 
limb’ [1]. 
Epidemiology: India is slowly progressing to the top of the world 
with the largest volume of diabetic subjects and is being anticipated 
to be the “diabetes capital of the world”. India will be the capital of 
diabetics by 2025. According to the Diabetes Atlas 2013 published 
by the International Diabetes Federation, the number of people with 
diabetes in India currently is 65.1 million, which is expected to rise 
to 142.7 million by 2035 unless urgent preventive steps are taken 
[2]. Up to 25% of patients with diabetes develop the corresponding 
ulcers of the foot. More than half of all foot ulcers become infected, 
requiring hospitalization, while 20% of infections result in 
amputation. Diabetes contributes approximately 80% of all non-
traumatic amputations performed every year. After a major 
amputation, 50% of people will have the other limb amputated 
within two years time. People with a history of diabetic foot ulcer 
have a 40% greater 10-year death rate than people with diabetes 
alone [3]. Of the total lower limb amputations, 85% are due to DFU 
[4]. Although recent population based data for Diabetic Foot Ulcer 
(DFU) is not available, it is estimated that approximately 45,000 legs 
are amputated every year in India [5]. 
Diabetes cost a whopping USD 548 billion in health expenditure 
globally in 2013. In a report published by Gupta S (2012), an average 
Indian should spend approximately 1960 USD for the complete 
treatment of neuro-ischemic foot [6]. 
Pathophysiology: DFU is a complex pathological phenomenon in 
which neuropathy and vasculopathy play a vital role and are 
together termed as neuro-ischemic ulcer. In most of the cases, 
infection is a consequence of neuro-ischemia and termed as neuro-
ischemic ulcers/DFU. In the majority cases of DFU in India, 
neuropathy (15%) and infections (7.6%) are foremost than vascular 
diseases (5%) [4]. 
The hyperglycemic condition in diabetes mellitus (Type 1 or Type 2) 
causes a range of pathological changes in diabetes patients, such as 
increased activity of protein kinase C, formation of advanced 
glycation end products and increased reactive oxygen species which 
leads to peripheral neuropathy. Micro and macrovascular diseases 
of blood vessels which supply blood to the foot lead to development 
of an ischemic state which engenders deficient nutrient blood supply 
to the foot and hence poor wound healing. 
Peripheral vascular disease, diabetic peripheral neuropathy, 
nephropathy, retinopathy, tobacco chewing, cigarette smoking, and 
alcohol consumption are the significant risk factors associated with 
DFUs. 
The treatment strategies available for DFUs include antibiotics 
(Piperacillin, Vancomycin), neuropathic drugs (symptomatic-
anticonvulsants, mechanism based- PKC inhibitors), dressings 
(collagen scaffolds), growth factors (rhEGF, PDGF, rhFGF), skin 
substitutes (Apligraf®, Dermagraft®
Unfortunately, none of the current treatment strategies address all 
the requirements to treat DFUs and also, the overall costs of these 
treatment strategies are high. Hence a single treatment strategy 
(multi-mechanism based drug/product) to satisfy all the 
requirements needs to be addressed or developed. 
), devices (hyperbaric oxygen 
therapy, Negative pressure therapy) and surgery (reconstruction 
and amputation).  
The most important factor in minimizing the overall cost of therapy 
is the development of novel drug delivery systems which will not 
increase the total cost, despite their high unit cost, if they are applied 
less frequently.  
In India, currently 12 clinical trials are underway (Table. 1), out of 
which 6 studies are topical, 4 studies are oral and 2 studies are 
observational. Of special importance is the fact that, of the 12 clinical 
trials initiated for diabetic foot therapy, herbal and homeopathic 
trials constitute a total of 4 trials [7]. 
Over the years, topical therapy has evolved with specific advantages 
to its reputation, which include high local concentration of the drug 
rather than systemic levels, restriction of total antibiotic usage and 
respite from the systemic toxicity. Established reports on collagen 
sponges and local application of gentamycin hint at it being a 
dependable method for the treatment of diabetic foot infections. 
Resistance development to single antibiotic administration is a 
common phenomenon well studied for decades; so the logical 
conclusion arising out of this is to include a combination of 
antimicrobial agents in tandem with surgery, debridement or 
osseous resection. 
“Every 30 seconds a lower limb is lost somewhere in the world as a 
consequence of diabetes” [8] - The concerns arising from DFUs are 
such that, aside from developing countries, developed countries are 
depicting high rates of amputation, thereby providing us with a clear 
picture of the scale of impact this disorder has had world over. In 
spite of this, the appeal of knowledge, attitude and practice of 
diabetic foot care has not picked up around the globe, with respect 
to DFU incidence, especially in India.  The situation has so deepened, 
that a system of rapid prevention with maximum compliance must 
be established for immediate application for all patients. National 
programs that raise awareness on diabetes and its corresponding 
complications on the feet are the need of the hour. 
“Prevention is better than cure”- There is no worthy situation for the 
application of this adage than in diabetic foot care. Constant risk 
assessment and its classification along with consecrated diabetic 
care by both health care specialists and others will help to achieve 
the ultimate goal of diabetic foot ulcer prevention. Typical situations 
of ulcer managements requires sound fundamental accesses to the 
multiple factors involved with special attention to the microbiology 
of the infections. For established ulcers an organized web of 
qualified practitioners is essential to guarantee viable treatment 
strategies that provide the best of both worlds; comply with clinical 
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guidelines and ensure patient satisfaction. Therefore, a technically 
capable practitioner is of utmost importance for patient specific 
diagnosis and therapy management. As a number of biochemical 
shortcomings/variations eventually cause DFUs, a single pronged 
treatment strategy holds no promise. Management therapies of the 
future must take into consideration the inherent pathological 
complexities and ensure authentic redressal of the inadequacies 
arising out of DFUs and eventually, patient satisfaction. 
 





Type of trial Mechanism 
1.  ReliDerm® Interventional DT Allogeneic fibroblast graft. 
(Dermal tissue equivalent). 
2.  HO/03/03 Interventional PKCa activation and PKCd inhibition, migration of skin cells 
across the wound gap to provide complete re-epithelialization. 
3.  Platelet derived growth factor (PDGF-BB) Interventional Stimulates chemotaxis and synthesis of fibroblasts and smooth 
muscle cells. 
4.  Diperoxochloric acid Interventional Derived from dichloric acid, stimulate skin growth and 
disinfection. 
5.  GranexinTM Interventional  Gel Stabilizes gap junctions/ tight junctions of endothelial cells 
during the wound healing process 
6.  Esmolol hydrochloride Interventional Increased vascular perfusion. 
7.  Linezolid 1200mg SR Tablet Interventional Bactericidal activity on Staphylococcus aureus 
8.  Katupila fresh leaf kalka with till taila Interventional Antiseptic and its paste is used in folklore to extract any 
extraneous materials from body tissues without surgery 
9.  Homoeopathic medicines Sulph Sil Lyc Ars. Interventional - 
10.  Homoeopathic medicine with ulcer dressing using 
Calendula Q 
Interventional Antioxidant activity 
11.  A survey on awareness of foot problem and care 
among diabetic population in India 
Observational - 
12.  Estimate of prevalence of depression in Type2 
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